Marker Therapeutics (NASDAQ:MRKR) is a biopharmaceutical company focused on the development of next-generation T cell-based immunotherapies for the treatment of hematologic malignancies and solid tumor cancers. The company is dedicated to advancing the field of cancer therapy with an innovative approach that involves tailoring treatments to the specific characteristics of a patient's tumor. Marker Therapeutics' projects include a range of multi-tumor antigen T cell therapies aimed at improving the safety and efficacy of cancer treatment. Its objectives are centered on improving patient outcomes through the research and development of targeted therapies that offer a potential for less toxic, more effective cancer care. The company's commitment to innovation and patient care drives its efforts in exploring new pathways and treatments in the fight against cancer.